Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis
© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA..
BACKGROUND: Despite newer treatments with immunosuppressive agents, there still exists a considerable morbidity and mortality risk among patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Since 1994 the European Vasculitis Society (EUVAS) has aimed for an improved outcome for patients with AAV, conducting several prospective randomized controlled trials (RCTs). The aim for the present study was to further evaluate the long-term survival of patients with AAV included in seven RCTs conducted by the EUVAS as well as to identify potential prognostic factors.
METHODS: Long-term follow-up data were collected from questionnaires sent to the principal investigators of the original RCTs (1995-2012): MEPEX, NORAM, CYCAZAREM, CYCLOPS, IMPROVE, RITUXVAS and MYCYC, comprising 848 patients, all newly diagnosed with AAV. Relative survival estimates are presented for the study cohorts. Demographic, clinical and laboratory characteristics at trial entry were studied as potential prognostic factors in multivariable models.
RESULTS: A total of 478 (56%) patients had granulomatosis with polyangiitis (GPA) and 370 (44%) had microscopic polyangiitis (MPA) with a mean age at diagnosis of 58 ± 14 years. The median follow-up time was 8 years (interquartile range 2.9-13.6). During the observation period there were 305 deaths and the main causes were infections (26%), cardiovascular disease (14%) and malignancies (13%). When compared with a matched cohort (regarding country, age group and sex) from the background population there were 14.2% more deaths among our cohort of AAV patients at 5 years, 19.9% at 10 years, 28.8% at 15 years and 36.3% at 20 years. The excess mortality occurred in all age groups. The estimated median survival time (from diagnosis) was 17.8 years (95% confidence interval 15.7-20). Among variables measured at baseline, advanced age, male sex, low estimated glomerular filtration rate and low platelet count were identified as predictors of death in a multivariate Cox model.
CONCLUSIONS: Patients with AAV still have an increased risk of mortality compared with the general population despite newer therapeutic regimens. Treatment complications and organ damage are the main causes of limited survival and infections remain the leading cause of mortality among patients with AAV.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association - 38(2023), 7 vom: 30. Juni, Seite 1655-1665 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sánchez Álamo, Beatriz [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ANCA-associated vasculitis |
|---|
| Anmerkungen: |
Date Completed 03.07.2023 Date Revised 16.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ndt/gfac320 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351283250 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351283250 | ||
| 003 | DE-627 | ||
| 005 | 20231226051003.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ndt/gfac320 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1170.xml |
| 035 | |a (DE-627)NLM351283250 | ||
| 035 | |a (NLM)36617233 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sánchez Álamo, Beatriz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.07.2023 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the ERA. | ||
| 520 | |a BACKGROUND: Despite newer treatments with immunosuppressive agents, there still exists a considerable morbidity and mortality risk among patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Since 1994 the European Vasculitis Society (EUVAS) has aimed for an improved outcome for patients with AAV, conducting several prospective randomized controlled trials (RCTs). The aim for the present study was to further evaluate the long-term survival of patients with AAV included in seven RCTs conducted by the EUVAS as well as to identify potential prognostic factors | ||
| 520 | |a METHODS: Long-term follow-up data were collected from questionnaires sent to the principal investigators of the original RCTs (1995-2012): MEPEX, NORAM, CYCAZAREM, CYCLOPS, IMPROVE, RITUXVAS and MYCYC, comprising 848 patients, all newly diagnosed with AAV. Relative survival estimates are presented for the study cohorts. Demographic, clinical and laboratory characteristics at trial entry were studied as potential prognostic factors in multivariable models | ||
| 520 | |a RESULTS: A total of 478 (56%) patients had granulomatosis with polyangiitis (GPA) and 370 (44%) had microscopic polyangiitis (MPA) with a mean age at diagnosis of 58 ± 14 years. The median follow-up time was 8 years (interquartile range 2.9-13.6). During the observation period there were 305 deaths and the main causes were infections (26%), cardiovascular disease (14%) and malignancies (13%). When compared with a matched cohort (regarding country, age group and sex) from the background population there were 14.2% more deaths among our cohort of AAV patients at 5 years, 19.9% at 10 years, 28.8% at 15 years and 36.3% at 20 years. The excess mortality occurred in all age groups. The estimated median survival time (from diagnosis) was 17.8 years (95% confidence interval 15.7-20). Among variables measured at baseline, advanced age, male sex, low estimated glomerular filtration rate and low platelet count were identified as predictors of death in a multivariate Cox model | ||
| 520 | |a CONCLUSIONS: Patients with AAV still have an increased risk of mortality compared with the general population despite newer therapeutic regimens. Treatment complications and organ damage are the main causes of limited survival and infections remain the leading cause of mortality among patients with AAV | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ANCA-associated vasculitis | |
| 650 | 4 | |a autoimmune diseases | |
| 650 | 4 | |a granulomatosis with polyangiitis | |
| 650 | 4 | |a microscopic polyangiitis | |
| 650 | 4 | |a prognostic factors | |
| 650 | 4 | |a survival | |
| 650 | 7 | |a Antibodies, Antineutrophil Cytoplasmic |2 NLM | |
| 700 | 1 | |a Moi, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Bajema, Ingeborg |e verfasserin |4 aut | |
| 700 | 1 | |a Faurschou, Mikkel |e verfasserin |4 aut | |
| 700 | 1 | |a Flossmann, Oliver |e verfasserin |4 aut | |
| 700 | 1 | |a Hauser, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Hruskova, Zdenka |e verfasserin |4 aut | |
| 700 | 1 | |a Jayne, David |e verfasserin |4 aut | |
| 700 | 1 | |a Luqmani, Raashid |e verfasserin |4 aut | |
| 700 | 1 | |a Mahr, Alfred |e verfasserin |4 aut | |
| 700 | 1 | |a Åkesson, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Westman, Kerstin |e verfasserin |4 aut | |
| 700 | 0 | |a EUVAS |e verfasserin |4 aut | |
| 700 | 1 | |a Andreas, Kronbichler |e investigator |4 oth | |
| 700 | 1 | |a Irmgard, Neumann |e investigator |4 oth | |
| 700 | 1 | |a Daniel, Blockmans |e investigator |4 oth | |
| 700 | 1 | |a Alain, Le Moine |e investigator |4 oth | |
| 700 | 1 | |a Zdenka, Hruskova |e investigator |4 oth | |
| 700 | 1 | |a Vladimir, Tesar |e investigator |4 oth | |
| 700 | 1 | |a Mikkel, Faurschou |e investigator |4 oth | |
| 700 | 1 | |a Wladimir, Szpirt |e investigator |4 oth | |
| 700 | 1 | |a Agneta, Ekstrand |e investigator |4 oth | |
| 700 | 1 | |a Anna, Salmela |e investigator |4 oth | |
| 700 | 1 | |a Alfred, Mahr |e investigator |4 oth | |
| 700 | 1 | |a Solange, Gonzalez Chiappe |e investigator |4 oth | |
| 700 | 1 | |a Marion, Haubitz |e investigator |4 oth | |
| 700 | 1 | |a Raoul, Bergner |e investigator |4 oth | |
| 700 | 1 | |a Michaela, Streubert |e investigator |4 oth | |
| 700 | 1 | |a Matthias, Schaier |e investigator |4 oth | |
| 700 | 1 | |a Wilhelm, Schmitt |e investigator |4 oth | |
| 700 | 1 | |a Ulf, Schönenmarck |e investigator |4 oth | |
| 700 | 1 | |a Kirsten, De Groot |e investigator |4 oth | |
| 700 | 1 | |a Smaragdi, Marinaki |e investigator |4 oth | |
| 700 | 1 | |a John, Boletis |e investigator |4 oth | |
| 700 | 1 | |a Mark, Little |e investigator |4 oth | |
| 700 | 1 | |a Gina, Gregorini |e investigator |4 oth | |
| 700 | 1 | |a Augusto, Vaglio |e investigator |4 oth | |
| 700 | 1 | |a Federico, Alberici |e investigator |4 oth | |
| 700 | 1 | |a Sinico, Renato |e investigator |4 oth | |
| 700 | 1 | |a Giacomo, Garibotto |e investigator |4 oth | |
| 700 | 1 | |a Annalisa, Carta |e investigator |4 oth | |
| 700 | 1 | |a Marisa, Santostefano |e investigator |4 oth | |
| 700 | 1 | |a Maria, Brugnano Rachele |e investigator |4 oth | |
| 700 | 1 | |a Jolanta, Dadoniene |e investigator |4 oth | |
| 700 | 1 | |a Ingeborg, Bajema |e investigator |4 oth | |
| 700 | 1 | |a Annelies, Berden |e investigator |4 oth | |
| 700 | 1 | |a Onno, Teng |e investigator |4 oth | |
| 700 | 1 | |a Maria, Cid |e investigator |4 oth | |
| 700 | 1 | |a Georgina, Espigol |e investigator |4 oth | |
| 700 | 1 | |a Jose, Ballarin |e investigator |4 oth | |
| 700 | 1 | |a Isabel, García |e investigator |4 oth | |
| 700 | 1 | |a Luis, Quintana |e investigator |4 oth | |
| 700 | 1 | |a Pérez, Fernández Elia |e investigator |4 oth | |
| 700 | 1 | |a María, Fernández Juárez Gema |e investigator |4 oth | |
| 700 | 1 | |a Beatriz, Sánchez Álamo |e investigator |4 oth | |
| 700 | 1 | |a Thomas, Hauser |e investigator |4 oth | |
| 700 | 1 | |a Thomas, Neumann |e investigator |4 oth | |
| 700 | 1 | |a Carlo, Chizzolini |e investigator |4 oth | |
| 700 | 1 | |a Jean-François, Balavoine |e investigator |4 oth | |
| 700 | 1 | |a Laura, Moi |e investigator |4 oth | |
| 700 | 1 | |a Annette, Bruchfeld |e investigator |4 oth | |
| 700 | 1 | |a Mårten, Segelmark |e investigator |4 oth | |
| 700 | 1 | |a Kerstin, Westman |e investigator |4 oth | |
| 700 | 1 | |a Anna, Åkesson |e investigator |4 oth | |
| 700 | 1 | |a Iva, Gunnarsson |e investigator |4 oth | |
| 700 | 1 | |a David, Jayne |e investigator |4 oth | |
| 700 | 1 | |a Lorraine, Harper |e investigator |4 oth | |
| 700 | 1 | |a Oliver, Flossmann |e investigator |4 oth | |
| 700 | 1 | |a Raashid, Luqmani |e investigator |4 oth | |
| 700 | 1 | |a Steve, Mcadoo |e investigator |4 oth | |
| 700 | 1 | |a Peter, Lanyon |e investigator |4 oth | |
| 700 | 1 | |a Alan, Salama |e investigator |4 oth | |
| 700 | 1 | |a Karen, Dahlsveen |e investigator |4 oth | |
| 700 | 1 | |a Joe, Rosa |e investigator |4 oth | |
| 700 | 1 | |a Joe, Barrett |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association |d 1990 |g 38(2023), 7 vom: 30. Juni, Seite 1655-1665 |w (DE-627)NLM012639206 |x 1460-2385 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g number:7 |g day:30 |g month:06 |g pages:1655-1665 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ndt/gfac320 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |e 7 |b 30 |c 06 |h 1655-1665 | ||